(Q38294626)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25525858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

review article

1 reference

title

Genetic and molecular targets in lymphoma: implications for prognosis and treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25525858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25525858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

author name string

Lohith S Bachegowda

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25525858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

language of work or name

English

0 references

publication date

1 December 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25525858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25525858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

volume

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25525858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

issue

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25525858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

page(s)

2509-2528

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25525858%20AND%20SRC:MED&resulttype=core&format=json

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

25 February 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Double-hit B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

The role of BCL6 in lymphomas and routes to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Cyclin D1 and human neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Chromosome-mediated alterations of the MYC gene in human cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

The MYC oncogene as a cancer drug target

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

BET bromodomain inhibition as a therapeutic strategy to target c-Myc

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Thalidomide and lenalidomide: Mechanism-based potential drug combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Lenalidomide in lymphomas and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Monocyte chemoattractant protein-1 (MCP-1): an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Role of chemokines in tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Serum biomarkers of immune activation and subsequent risk of non-hodgkin B-cell lymphoma among HIV-infected women

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Expression of programmed death-1 in primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma, cutaneous pseudo-T-cell lymphoma, and other types of cutaneous T-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Follicular programmed death 1-positive lymphocytes in the tumor microenvironment are an independent prognostic factor in follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

The microenvironment of AIDS-related diffuse large B-cell lymphoma provides insight into the pathophysiology and indicates possible therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Molecular mechanisms of T-cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Releasing the brake on the immune system: ipilimumab in melanoma and other tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Epigenetics and B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Nonhistone protein acetylation as cancer therapy targets

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

HDAC inhibitor-based therapies and haematological malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Signal transduction inhibitors in treatment of myelodysplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

NF-kappaB functions as a tumour promoter in inflammation-associated cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

NF-κB and IRF7 pathway activation by Epstein-Barr virus Latent Membrane Protein 1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Epstein-Barr virus LMP2A imposes sensitivity to apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Time to treatment response in patients with follicular lymphoma treated with bortezomib is longer compared with other histologic subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

The emerging mechanisms of isoform-specific PI3K signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Mutation analysis of the tyrosine phosphatase PTPN2 in Hodgkin's lymphoma and T-cell non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Anaplastic lymphoma kinase (ALK) activates Stat3 and protects hematopoietic cells from cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Cooperative epigenetic modulation by cancer amplicon genes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Association of JAK-STAT pathway related genes with lymphoma risk: results of a European case-control study (EpiLymph).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Targeting pathological B cell receptor signalling in lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

B cell antigen receptor-induced activation of Akt promotes B cell survival and is dependent on Syk kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Protein kinase C and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Retrospective analysis of protein kinase C-beta (PKC-beta) expression in lymphoid malignancies and its association with survival in diffuse large B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

High immunohistochemical expression of p-AKT predicts inferior survival in patients with diffuse large B-cell lymphoma treated with immunochemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

Histone deacetylase inhibitors potently repress CXCR4 chemokine receptor expression and function in acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.14.112

21 January 2018

Identifiers

DOI

10.2217/FON.14.112

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25525858%20AND%20SRC:MED&resulttype=core&format=json

25 February 2020

1 reference